en.Wedoany.com Reported - MGI Tech Co., Ltd. (MGI) showcased its latest advancements in sequencing, automation, and clinical genomics at the 2026 European Society of Human Genetics (ESHG) conference in Gothenburg, Sweden. At booth 352, MGI presented its portfolio of sequencing and automation solutions to researchers, clinicians, laboratory leaders, and industry partners, while announcing new initiatives aimed at strengthening collaboration within the genomics ecosystem.
A key highlight of the conference was the launch of the MGI NGS Partner Enablement Program. This program targets diagnostic developers, testing providers, and laboratory partners seeking to build validated clinical workflows on MGI sequencing platforms. It aims to accelerate the development and adoption of regulated next-generation sequencing (NGS) applications by fostering collaboration to streamline workflow implementation, reduce time-to-market, and support broader access to precision medicine solutions. Fang Chen, General Manager of MGI Europe and Africa, stated that clinical genomics increasingly relies on robust partnerships across the value chain, and this program creates a collaborative framework that brings together assay developers, software providers, automation partners, and clinical laboratories to accelerate access to high-quality genomic testing.
MGI also announced new original equipment manufacturer (OEM) collaboration opportunities for the MGI DE Suite (integrated library preparation and sequencing platform) at ESHG 2026, offering turnkey automation solutions to global partners. The DE Suite includes the current D4+E25 combination, as well as the new D16 paired with the E25, featuring a new 50M flow cell. The D16, launching later this year, is a benchtop, low-to-medium throughput library preparation system and a successor to the D4; it retains a fully enclosed contamination-proof system and integrates a single-channel robotic pipetting module to maximize automation. Equipped with two sample preparation cassettes, each processing eight samples, the D16 offers significantly higher throughput. The D16 and E25 systems provide a flexible and scalable automation solution for library construction, sequencing, and bioinformatics analysis. Through this open OEM framework, MGI enables customers and solution providers to integrate validated automation technologies into customized workflows tailored for specific clinical and research applications. Wim Vervaeke, OEM Director of MGI Europe and Africa, noted that by offering the D16 platform, MGI expands opportunities for OEM partners to develop truly hands-free solutions that simplify and automate complex laboratory workflows. MGI's innovative products, including PrepALL, E25, and G99, have already inspired new partnerships within the life sciences ecosystem. By combining MGI's automation expertise with partners' specialized capabilities, both parties are creating integrated solutions that deliver maximum value, efficiency, and convenience to end users.
As part of ESHG 2026, MGI hosted a corporate satellite symposium titled "Advancing Diagnostics: From Clinical Implementation to Biomarker Discovery," bringing together experts from across Europe to showcase how advanced genomic technologies translate into tangible clinical and research impacts. During the symposium, Dr. Raquel T. Lima from IPATIMUP in Portugal presented the clinical value of RNA sequencing in detecting actionable gene fusions in solid tumors, improving diagnostic rates and supporting precision oncology decisions; Professor Dr. Andreas Braun from the University Hospital Schleswig-Holstein in Germany shared how spatial biology techniques map the tumor microenvironment in melanoma, revealing tumor heterogeneity, cellular interactions, and mechanisms related to disease progression and treatment response; Dr. Andrea Conti from BMR Genomics in Italy explored opportunities for whole-genome sequencing in assessing pharmacogenetic markers, emphasizing how comprehensive genomic approaches support the implementation of personalized medicine by improving the identification of clinically relevant variants. Together, these presentations demonstrated how genomic and multi-omics technologies advance clinical diagnostics, translational oncology research, and precision medicine, while highlighting the growing role of sequencing in delivering actionable insights across healthcare and biomedical research.
MGI showcased its ultra-high-throughput sequencing platform, the T7+, at the exhibition, underscoring its strong market adoption. Since its official launch for the European and African regions at the Analytica trade fair in Munich in 2026, the platform had 27 units installed globally by the end of 2025. MGI also presented a range from benchtop to ultra-high-throughput sequencing platforms, along with advanced laboratory automation solutions, supporting researchers seeking high-performance, scalable, and cost-effective genomics workflows. Dr. Christian Zimmerman, Vice President of Sales for MGI Europe and Africa, stated that MGI's mission goes beyond providing innovative technology; it focuses on building a complete ecosystem that enables customers to seamlessly transition from research to clinical implementation. The partnerships and initiatives launched demonstrate MGI's commitment to making genomic technology more accessible, integrated, and impactful.
Europe is a strategic region for MGI. With increasing adoption of genomic technologies by research institutions, healthcare systems, and national-level population programs, MGI is helping accelerate the transition to a more precise, data-driven healthcare model through continued investment in sequencing innovation, automation, clinical collaboration, and collaborative ecosystem development. As genomics becomes increasingly integrated into routine clinical practice, MGI remains committed to providing the necessary technologies and partnerships to support the next generation of precision medicine.
Founded in 2016, MGI focuses on the research, development, manufacturing, and sales of instruments, reagents, and related products in the life sciences and biotechnology fields. The company provides real-time, multi-omics, and comprehensive digital equipment and systems for precision medicine, agriculture, healthcare, and various other industries. As one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers, MGI offers scalable sequencing capabilities from Gb to Tb levels to global users. MGI is also one of the only suppliers providing a full-stack product portfolio covering three core segments: SEQ ALL (short-read and long-read sequencing), GLI (Generative Laboratory Intelligence), and multi-omics. Leveraging its expertise and product layout in the life sciences, MGI is continuously advancing the development of life sciences.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
